Roche seeks new use for cancer blockbuster Herceptin; AZ's Seroquel gets recommendation in depression;

@FiercePharma:  Doctors sign on to tough conflicts-of-interest rulesDoctors sign on to tough conflicts-of-interest rules. Article |  Follow @FiercePharma

> AstraZeneca's schizophrenia drug Seroquel XR has been recommended by European regulators as an add-on treatment for depression, following an earlier rebuff in the Netherlands. Report

> Roche subsidiary Genentech filed cancer drug Herceptin for FDA approval for a new use in treating patients with advanced stomach cancer, potentially extending its blockbuster market. Report

> A U.S. judge ruled that some patent claims covering Merck's cholesterol drug Zetia were invalid, but that other claims were valid. Report

> Pfizer shareholders overwhelmingly rejected a proposal to stop giving top executives stock options, but the company's CEO still took some heat over that issue and Pfizer's low stock price. Report

> Shareholders of Johnson & Johnson narrowly rejected a proposal to give themselves a "say on pay'' of top executives yesterday, but the close vote--52 percent against and 48 percent for--might not be final. Report

> Celgene is battling Canada's Patented Medicine Prices Review Board over the agency's insistence on getting pricing info for multiple myeloma treatment Thalomid. Report

> Pfizer said Thursday it will pay a dividend of 18 cents per share for the second quarter of 2010. Report

Biotech News

 @FierceBiotech: Biotechs tackle new frontiers in vaccine production. Report | Follow @FierceBiotech   

  @JohnCFierce: It looks like just about every biotech out there wants a piece of the new $1B federal tax credit/grant. Report | Follow @JohnCFierce

> Vatican backs adult stem cell research with $2.7M. Story

> Study: Pyramax works as well as Coartem for malaria. Item

> EU recommends Daxas approval following FDA panel rejection. Report

> Regenerative medicine could be $20B market in 15 years. Story

> In 19-1 vote, FDA panel rejects Acurox. Item

And Finally... Should the FDA open the door to off-label marketing? Report